FDA clears Medtronic nerve ablation device for chronic pain

Medtronic HQ
The Accurian platform can perform standard and pulsed ablation procedures, using internally cooled RF probes. (Medtronic)

Medtronic has received an FDA clearance for its Accurian radiofrequency ablation system for nerve tissues, designed to treat chronic pain through a minimally invasive procedure.

The device uses radio waves to generate heat that burns out small patches of nerves to stop them from sending pain signals—while using advanced software to help control the amount of power delivered and the temperature of the procedure, for more consistent and predictable lesion formations.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

According to Medtronic, the Accurian platform can perform standard and pulsed ablation procedures, using internally cooled RF probes to create a range of lesion shapes, sizes and volumes while allowing the physician to control each current channel independently.

Disabling pain lasting more than three to six months affects at least 100 million adults in the U.S., Medtronic said, with related treatment and lost productivity costs reaching $635 billion a year.

RELATED: The top 10 medtech companies of 2024 | Medtronic

The medtech giant previously received FDA approval and a CE mark for its Intellis spinal cord stimulation implant for chronic intractable pain. The neurostimulator also records the patient’s activity and movement, so physicians can track how well the program is treating pain.

Suggested Articles

The Tel Aviv-based VC firm focused on digital health has closed a new fund totaling $170 million, with plans to expand to the Asia Pacific region.

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.